Peregrine Asset Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

Peregrine Asset Advisers’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-403	Closed	-$424K	–	185
2024 Q3	$424K	Buy	+403	New	+$448K	0.15%	112
2024 Q2	–	Sell	-303	Closed	-$292K	–	182
2024 Q1	$292K	Hold	303	–	–	0.12%	133
2023 Q4	$266K	Hold	303	–	–	0.13%	129
2023 Q3	$249K	Hold	303	–	–	0.13%	125
2023 Q2	$218K	Hold	303	–	–	0.17%	69
2023 Q1	$249K	Sell	303 -400	-57%	-$302K	0.24%	57
2022 Q4	$507K	Buy	+703	New	+$519K	0.54%	31
2021 Q4	–	Sell	-4,162	Closed	-$2.52M	–	149
2021 Q3	$2.52M	Buy	+4,162	New	+$2.58M	1.29%	29
2020 Q3	–	Sell	-7,170	Closed	-$4.47M	–	114
2020 Q2	$4.47M	Buy	7,170 +2,537	+55%	+$1.44M	2.54%	12
2020 Q1	$2.26M	Buy	+4,633	New	+$1.91M	1.7%	17

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Peregrine Asset Advisers's REGN Position: Q4 2024 in Review

Peregrine Asset Advisers sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 403 shares — an estimated $424K sold.

Peregrine Asset Advisers first reported a position in REGN in Q1 2020 and held it in 10 quarters. The position peaked at $4.47M in Q2 2020. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Peregrine Asset Advisers reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Peregrine Asset Advisers sold 403 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $424K.
Peregrine Asset Advisers first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 10 quarters.
Peregrine Asset Advisers's Regeneron Pharmaceuticals position peaked at $4.47M in Q2 2020.
1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Peregrine Asset Advisers's 13F filing for Q4 2024, filed 3 Feb 2025.